Overview

Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax

Status:
Recruiting
Trial end date:
2025-07-22
Target enrollment:
Participant gender:
Summary
Single center, open-label, phase 2 study to determine the efficacy of cirmtuzumab consolidation in patients with measurable disease on venetoclax.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Diego
Collaborator:
Oncternal Therapeutics, Inc
Treatments:
Venetoclax